Bicalutamide causes heart failure in an elderly patient with prostate cancer

References

• Furr BJA, Tucker H. The preclinical development of bicalutamide: pharmacodynamics and mechanism of action. Urology. 1996;47:13–35.
   PubMed Web of Science ®Google Scholar
• Georget V, Térouanne B, Nicolas J-C, et al. Mechanism of antiandrogen action: key role of Hsp90 in conformational change and transcriptional activity of the androgen receptor. Biochemistry. 2002;41:11824–11831. DOI:10.1021/bi0259150.
   PubMed Web of Science ®Google Scholar
• Floyd MSJ, Teahan SJ, Fitzpatrick JM, et al. Differential mechanisms of bicalutamide-induced apoptosis in prostate cell linesBicalutamide-induced apoptosis in prostate cell lines. Prostate Cancer Prostatic Dis. 2008;12:25–33.
   PubMed Web of Science ®Google Scholar
• Morrissey C, Brown M, O’Sullivan J, et al. Epigallocatechin-3-gallate and bicalutamide cause growth arrest and apoptosis in NRP-152 and NRP-154 prostate epithelial cells. Int J of Urol. 2007;14:545–551. DOI:10.1111/j.1442-2042.2007.01774.x.
   PubMed Web of Science ®Google Scholar
• Product Information: Casodex(R), bicalutamide (2000d) Zeneca Pharmaceuticals, Wilmington, DE.
   Google Scholar
• Cockshott ID, Cooper KJ, Sweetmore DS, et al. The pharmacokinetics of Casodex in prostate cancer patients after single and during multiple dosing. Eur Urol. 1990;18:10–17.
   PubMed Web of Science ®Google Scholar
• Kolvenbag GJCM, Blackledge GRP, Gotting-Smith K. Bicalutamide (Casodex®) in the treatment of prostate cancer: history of clinical development. Prostate. 1998;34:61–72.
   PubMed Web of Science ®Google Scholar
• Writing Group. Micromedex: Thomson Healthcare [ cited 2015 Mar 13].
   Google Scholar
• Iversen P. The third analysis of the bicalutamide Early Prostate Cancer programme. BJU Int. 2006;97:438–439.
   PubMed Web of Science ®Google Scholar
• Naranjo CA, Busto U, Sellers EM, et al. A method for estimating the probability of adverse drug reactions. Clin Pharmacol Ther. 1981;30:239–245.
   PubMed Web of Science ®Google Scholar
• Sternberg CN. Apples and oranges. BJU Int. 2006;97:435–443.
   PubMed Web of Science ®Google Scholar
• Albertsen PC, Klotz L, Tombal B, et al. Cardiovascular morbidity associated with gonadotropin releasing hormone agonists and an antagonist. Eur Urol. 2014;65:565–573.
   PubMed Web of Science ®Google Scholar
• Dockery F, Bulpitt CJ, Agarwal S, et al. Anti-androgens increase N-terminal pro-BNP levels in men with prostate cancer. Clin Endocrin. 2008;68:59–65. DOI:10.1111/j.1365-2265.2007.02999.x.
   PubMed Web of Science ®Google Scholar
• Ikeda Y, Aihara K, Yoshida S, et al. Androgen-androgen receptor system protects against angiotensin II-induced vascular remodeling. Endocrin. 2009;150:2857–2864. DOI:10.1210/en.2008-1254.
   PubMed Web of Science ®Google Scholar
• Nakamura M. Peripheral vascular remodeling in chronic heart failure: clinical relevance and new conceptualization of its mechanisms. J Card Fail. 1999;5(2):127–138.
   PubMed Web of Science ®Google Scholar
• Poelzl G, Frick M, Huegel H, et al. Chronic heart failure is associated with vascular remodeling of the brachial artery. Eur J Heart Fail. 2005;7(1):43–48. DOI:10.1016/j.ejheart.2004.04.008.
   PubMed Web of Science ®Google Scholar
• Ikeda Y, Aihara K, Sato T, et al. Androgen Receptor Gene Knockout Male Mice Exhibit Impaired Cardiac Growth and Exacerbation of Angiotensin II-induced Cardiac Fibrosis. J Biol Chem. 2005;280:29661–29666.
   PubMed Web of Science ®Google Scholar
• Mäkinen J, Järvisalo MJ, Pöllänen P, et al. Increased Carotid Atherosclerosis in Andropausal Middle-Aged Men. J Am Coll Cardiol. 2005;45(10):1603–1608.
   PubMed Web of Science ®Google Scholar
• Muller M, van den Beld AW, Bots ML, et al. Endogenous sex hormones and progression of carotid atherosclerosis in elderly men. Circulation. 2004;109:2074–2079.
   PubMed Web of Science ®Google Scholar
• Polak JF, Meisner A, Pencina MJ, et al. Incident congestive heart failure and common carotid artery diameter: the Framingham offspring study. Circulation. 2011;124:A13709.
   Google Scholar
• Gottdiener JS, Arnold AM, Aurigemma GP, et al. Predictors of congestive heart failure in the elderly: the cardiovascular health study. J Am Coll Cardiol. 2000;35(6):1628–1637.
   PubMed Web of Science ®Google Scholar
• Trachtenberg J. Emerging pharmacologic therapies for prostate cancer. Rev in Urol. 2001;3(3):S23–S28.
   PubMedGoogle Scholar
• D’Antonio JM. Analysis of endothelin during androgen deprivation: implications for prostate cancer progression [ Doctoral Dissertation]. Pittsburgh (PA): University of Pittsburgh; 2007.
   Google Scholar
• Feldman BJ, Feldman D. The development of androgen-independent prostate cancer. Nature Rev: Cancer. 2001;1:34–45.
   PubMed Web of Science ®Google Scholar
• Balk SP. Androgen receptor as a target in androgen-independent prostate cancer. Urology. 2002;60(3 Suppl 1):132–138.
   PubMed Web of Science ®Google Scholar
• Dai Z, Aoki T, Fukumoto Y, et al. Coronary perivascular fibrosis is associated with impairment of coronary blood flow in patients with non-ischemic heart failure. J Cardiol. 2012;60(5):416–421.
   PubMed Web of Science ®Google Scholar
• Jasmin J, Lucas M, Cernacek P, et al. Effectiveness of a Nonselective ETA/B and a Selective ETA Antagonist in Rats With Monocrotaline-Induced Pulmonary Hypertension. Circulation. 2001;103:314–318.
   PubMed Web of Science ®Google Scholar
• Ajayi AA, Fidelis P. The effect of flutamide on systemic and renal hemodynamics in Zucker diabetic rats: paradoxic renal vasodilator response to endothelin-1 and TXA2 receptor activation in female sex. J Cardiovasc Pharmacol. 2006;48(5):191–198.
   PubMed Web of Science ®Google Scholar
• Pflug B, McHugh K, D’Antonio J, et al. Defining the basis of an operational model for enhanced efficacy of combination therapy using an endothelin receptor antagonist and chemotherapeutic agents. Mol Cancer Ther. 2007;6:A287.
   Google Scholar
• Lüscher TF, Barton M. Endothelins and Endothelin Receptor Antagonists Therapeutic Considerations for a Novel Class of Cardiovascular Drugs. Circulation. 2000;102:2434–2440.
   PubMed Web of Science ®Google Scholar
• Gustafsson AB, Gottlieb RA. Bcl-2 family members and apoptosis, taken to heart. Am J Physiol - Cell Physiol. 2007;292(1):C45–C51.
   PubMed Web of Science ®Google Scholar
• Limana F, Urbanek K, Chimenti S, et al. bcl-2 overexpression promotes myocyte proliferation. PNAS. 2002;99(9):6257–6262.
   PubMed Web of Science ®Google Scholar
• Katayama H, Murashima T, Saeki Y, et al. The pure anti-androgen bicalutamide inhibits cyclin A expression both in androgen-dependent and -independent cell lines. Int J Oncol. 2010;36:553–562.
   PubMed Web of Science ®Google Scholar
• Woo YJ, Panlilio CM, Cheng RK, et al. Therapeutic Delivery of Cyclin A2 Induces Myocardial Regeneration and Enhances Cardiac Function in Ischemic Heart Failure. Circulation. 2006;114(1 Suppl):I206–13.
   PubMed Web of Science ®Google Scholar
• Shapiro SD, Ranjan AK, Kawase Y, et al. Cyclin A2 induces cardiac regeneration after myocardial infarction through cytokinesis of adult cardiomyocytes. Sci Transl Medication. 2014;6(224):224–227.
   Google Scholar
• Cheng RK, Asai T, Tang H, et al. 2007. Cyclin A2 induces cardiac regeneration after myocardial infarction and prevents heart failure. Circulation Res. 100:1741–1748. DOI:10.1161/CIRCRESAHA.107.153544.
   PubMed Web of Science ®Google Scholar
• Heeneman S, Sluimer JC, Daemen MJAP. Angiotensin-Converting Enzyme and Vascular Remodeling. Circulation Res. 2007;101:441–454.
   PubMed Web of Science ®Google Scholar
• Irani K. Angiotensin II–stimulated vascular remodeling: the search for the culprit oxidase. Circulation Res. 2001;88:858–860.
   PubMed Web of Science ®Google Scholar